Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

515 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.
Lamers LM, Stupp R, van den Bent MJ, Al MJ, Gorlia T, Wasserfallen JB, Mittmann N, Jin Seung S, Crott R, Uyl-de Groot CA; EORTC 26981/22981 NCI-C CE3 Intergroup Study. Lamers LM, et al. Among authors: van den bent mj. Cancer. 2008 Mar 15;112(6):1337-44. doi: 10.1002/cncr.23297. Cancer. 2008. PMID: 18213621 Free article. Clinical Trial.
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
van den Bent MJ, Chinot O, Boogerd W, Bravo Marques J, Taphoorn MJ, Kros JM, van der Rijt CC, Vecht CJ, De Beule N, Baron B. van den Bent MJ, et al. Among authors: van der rijt cc. Ann Oncol. 2003 Apr;14(4):599-602. doi: 10.1093/annonc/mdg157. Ann Oncol. 2003. PMID: 12649108 Free article. Clinical Trial.
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros JM, van der Rijt CC, Vecht ChJ, Allgeier A, Gorlia T; European Organization for Research and Treatment of Cancer Brain Tumor Group. van den Bent MJ, et al. Among authors: van der rijt cc. J Clin Oncol. 2003 Jul 1;21(13):2525-8. doi: 10.1200/JCO.2003.12.015. J Clin Oncol. 2003. PMID: 12829671 Clinical Trial.
The role of chemotherapy in brain metastases.
van den Bent MJ. van den Bent MJ. Eur J Cancer. 2003 Oct;39(15):2114-20. doi: 10.1016/s0959-8049(03)00577-x. Eur J Cancer. 2003. PMID: 14522368 Review.
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme.
van den Bent MJ, Grisold W, Frappaz D, Stupp R, Desir JP, Lesimple T, Dittrich C, de Jonge MJ, Brandes A, Frenay M, Carpentier AF, Chollet P, Oliveira J, Baron B, Lacombe D, Schuessler M, Fumoleau P; European Organization for Research and Treatment of Cancer New Drug Development Group; European Organization for Research and Treatment of Cancer Brain Tumor Group. van den Bent MJ, et al. Ann Oncol. 2003 Dec;14(12):1732-4. doi: 10.1093/annonc/mdg491. Ann Oncol. 2003. PMID: 14630677 Free article. Clinical Trial.
Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
Triebels VH, Taphoorn MJ, Brandes AA, Menten J, Frenay M, Tosoni A, Kros JM, Stege EB, Enting RH, Allgeier A, van Heuvel I, van den Bent MJ. Triebels VH, et al. Among authors: van heuvel i, van den bent mj. Neurology. 2004 Sep 14;63(5):904-6. doi: 10.1212/01.wnl.0000137049.65631.db. Neurology. 2004. PMID: 15365146 Clinical Trial.
515 results